Add to ORKGThe Author(s) 2015. This article is published with open access at Springerlink.com Introduction: Fingolimod 0.5 mg is an orally active sphingosine 1-phosphate receptor modulator approved for use in adults with relapsing multiple sclerosis (MS). The efficacy and safety profile of fingolimod has been wel
Fingolimod approval was based mainly on two clinical trials, FREEDOMS and TRANSFORMS, which demonstr...
BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and...
The safety profile of fingolimod is well estab- lished in clinical trials and post-marketing studies...
Background: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for r...
1533-4406 (Electronic) 0028-4793 (Linking) Clinical Trial, Phase III Journal Article Multicenter Stu...
Background: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for r...
WOS: 000419248500004Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous s...
International audienceIntroduction: Fingolimod (Fg), a sphingosine 1-phosphate receptor modulator, d...
1533-4406 (Electronic) 0028-4793 (Linking) Comparative Study Journal Article Multicenter Study Rando...
BACKGROUND Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of...
Fingolimod is a sphingosine-1-phosphate (S1P)-receptor modulator and the first novel oral dis-ease-m...
Background: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and ...
Fingolimod is the fi rst in a new class of drugs—the sphingosine 1-phosphate receptor modulators—and...
Alberto Gajofatto,1,2 Marco Turatti,2 Salvatore Monaco,1,2 Maria Donata Benedetti2 1Department of Ne...
BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and...
Fingolimod approval was based mainly on two clinical trials, FREEDOMS and TRANSFORMS, which demonstr...
BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and...
The safety profile of fingolimod is well estab- lished in clinical trials and post-marketing studies...
Background: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for r...
1533-4406 (Electronic) 0028-4793 (Linking) Clinical Trial, Phase III Journal Article Multicenter Stu...
Background: Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is approved by EMA for r...
WOS: 000419248500004Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous s...
International audienceIntroduction: Fingolimod (Fg), a sphingosine 1-phosphate receptor modulator, d...
1533-4406 (Electronic) 0028-4793 (Linking) Comparative Study Journal Article Multicenter Study Rando...
BACKGROUND Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of...
Fingolimod is a sphingosine-1-phosphate (S1P)-receptor modulator and the first novel oral dis-ease-m...
Background: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and ...
Fingolimod is the fi rst in a new class of drugs—the sphingosine 1-phosphate receptor modulators—and...
Alberto Gajofatto,1,2 Marco Turatti,2 Salvatore Monaco,1,2 Maria Donata Benedetti2 1Department of Ne...
BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and...
Fingolimod approval was based mainly on two clinical trials, FREEDOMS and TRANSFORMS, which demonstr...
BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and...
The safety profile of fingolimod is well estab- lished in clinical trials and post-marketing studies...